The initial public offering (IPO) of Symbiotec Pharmalab Ltd opens for public subscription on 24 August 2026 and will remain open until 27 August 2026, inviting investors to bid within a price band of ₹938 to ₹988. This Mainboard issue is being listed on both the BSE and NSE, offering retail participation without any disclosed anchor investor allocation.
Symbiotec Pharmalab Ltd operates in the pharmaceuticals sector—with a specialized focus on active pharmaceutical ingredients, biotechnology and complex injectables—bringing a research-driven, science-based approach to drug manufacturing and APIs.
Retail investors keen on the Indian pharmaceutical domain may find this IPO a noteworthy opportunity, as the company leverages its capabilities in both conventional pharmaceutical chemistry and advanced biotechnological processes.
| Opens | 24 Aug 2026 |
| Closes | 27 Aug 2026 |
| Price Band | ₹938–₹988 |
| Lot Size | 15 shares |
No anchor investor allotment has been reported for this issue - this is typical for SME IPOs, which do not always carry an anchor round.
Follow live GMP and subscription numbers on the Symbiotec Pharmalab Ltd IPO page while the issue is open.